Nuvalent (NUVL) Free Cash Flow (2020 - 2026)
Nuvalent's (NUVL) quarterly Free Cash Flow came in at -$92.4 million in Q1 2026, down 68.55% YoY from -$293.8 million in Q1 2025, and down 26.01% on a QoQ basis from -$73.3 million in Q4 2025.
Nuvalent (NUVL) Free Cash Flow (2020 - 2026) Analysis & Trends
Nuvalent (NUVL) has 7 years of Free Cash Flow data on file, last reported at -$92.4 million in Q1 2026.
- Quarterly Free Cash Flow fell 68.55% year-over-year to -$92.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$312.8 million (down 53.48% YoY) and the FY2025 annual result came in at -$275.2 million, down 48.71% from the prior year.
- Free Cash Flow declined to -$92.4 million in Q1 2026, from -$73.3 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$13.5 million in Q1 2022 to a low of -$92.4 million in Q1 2026.
- A 5-year average of -$42.2 million and a median of -$36.1 million in 2024 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow sank 128.25% — and 2025, when it retreated 18.27%.
- Tracing NUVL's Free Cash Flow over 5 years: stood at -$17.8 million in 2022, then plunged by 69.91% to -$30.2 million in 2023, then plunged by 105.24% to -$62.0 million in 2024, then dropped by 18.27% to -$73.3 million in 2025, then slipped by 26.01% to -$92.4 million in 2026.
- The last three Free Cash Flow figures came in at -$92.4 million (Q1 2026), -$73.3 million (Q4 2025), and -$70.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Nuvalent | 9.10 Bn | 9.10 Bn | - | -92.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -92.40 Mn |
| Mar 31, 2026 | -92.40 Mn |
| Dec 31, 2025 | -73.33 Mn |
| Dec 31, 2025 | -73.33 Mn |
| Sep 30, 2025 | -70.46 Mn |
| Sep 30, 2025 | -70.46 Mn |
| Jun 30, 2025 | -76.60 Mn |
| Jun 30, 2025 | -76.60 Mn |
| Mar 31, 2025 | -54.82 Mn |
| Mar 31, 2025 | -54.82 Mn |
| Dec 31, 2024 | -62.00 Mn |
| Dec 31, 2024 | -62.00 Mn |
| Sep 30, 2024 | -45.82 Mn |
| Sep 30, 2024 | -45.82 Mn |
| Jun 30, 2024 | -41.16 Mn |
| Jun 30, 2024 | -41.16 Mn |
| Mar 31, 2024 | -36.09 Mn |
| Mar 31, 2024 | -36.09 Mn |
| Dec 31, 2023 | -30.21 Mn |
| Dec 31, 2023 | -30.21 Mn |